|
Updated AAP Visual Guide Supports RSV Immunization Decisions
The AAP’s updated RSV Immunization Administration Visual Guide, dated September 3, 2026, provides a quick reference for determining eligibility, selecting a product, and reviewing dosing. The flowchart considers patient age, maternal RSV vaccination, prior immunization, and risk factors for severe disease.
The guide includes the expanded high-risk groups recommended for nirsevimab (Beyfortus) during their second RSV season, at ages 8 through 19 months. These include children born before 32 weeks’ gestation; children with hemodynamically significant congenital heart disease; certain pulmonary abnormalities or neuromuscular disorders; and Down syndrome or other chromosomal differences associated with increased risk.
Share the guide with your clinical team and review the complete eligibility criteria and administration details.
View the AAP RSV visual guide.
|